Abstract：Objective To explore the short-term efficacy and safety of Anlotinib Hydrochloride in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Eighty patients with advanced NSCLC treated at the second line and above in the Second People’s Hospital of Wuhu City in Anhui Province from June 2018 to May 2021 were selected and they were divided into two groups according to random number table method, with 40 cases in each group. The observation group was treated with Anlotinib Hydrochloride, and the control group was given the best supportive treatment. After six weeks of treatment, the short-term curative effects (objective remission rate [ORR], disease control rate [DCR]), the levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA21-1) were compared between two groups. Karnofsky performance status (KPS) score and adverse reactions were observed in two groups. Results After treatment, ORR and DCR of observation group were higher than those of control group (P ＜ 0.05). After treatment, the levels of CEA and CYFRA21-1 in two groups were lower than those before treatment (P < 0.05), and observation group was lower than control group (P < 0.05). After treatment, KPS scores of two groups were higher than those before treatment (P ＜ 0.05), and those of observation group were higher than control group (P ＜ 0.05). The incidence rates of hand foot syndrome, proteinuria, hypertension, and oral mucositis in observation group were higher than those in control group (P < 0.05). Conclusion Anlotinib Hydrochloride has significant short-term efficacy and good safety in the treatment of NSCLC, and it can provide a new treatment for NSCLC patients with treatment failure, which is worthy of popularization and application.
[1] 窦妍，姜达.小分子抗血管生成药物在非小细胞肺癌中的研究进展[J].中国肺癌杂志，2021，24（1）：56-62.
[2] 徐聂，程思，罗无暇，等.安罗替尼治疗晚期非小细胞肺癌的疗效及安全性[J].中国新药与临床杂志，2021，40（3）：201-204.
[3] Han B，Li K，Wang Q，et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer：the ALTER 0303 phase 3 randomized clinical trial [J]. JAMA Oncol，2018，4（11）：1569-1575.
[4] 王芳，李真，滕影，等.安罗替尼治疗晚期肺癌疗效及短期预后影响因素分析[J].安徽医科大学学报，2021，56（3）：475-479，485.
[5] 孙魏，邹玺，张微，等.安罗替尼联合替吉奥二线治疗复发转移性食管鳞癌的临床疗效[J].南方医科大学学报，2021，41（2）：250-255.
[6] Zhou M，Chen X，Zhang H，et al. China National Medical Products Administration approval summary：Anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy [J]. Cancer Commun （Lond），2019，39（1）：36.
[7] Wang L，He Z，Yang S，et al. The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer （NSCLC）：a subgroup analysis of ALTER 0303 trial [J]. Transl Lung Cancer Res，2019，8（5）：575-583.
[8] 中华人民共和国卫生部医政司编.中国常见恶性肿瘤诊治规范[M].北京：北京医科大学、中国协和医科大学联合出版社，1991.
[9] 杨学宁，吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学，2004，4（2）：85-90.
[10] Hendrichova I，Castelli M，Mastroianni C，et al. Pressure ulcers in cancer palliative care patients [J]. Palliat Med，2010，24（7）：669-673.
[11] Liang L，Hui K，Hu C，et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells [J]. J Exp Clin Cancer Res，2019，38（1）：71.
[12] 刘艺婧，卢凯华.安罗替尼治疗肺癌的临床研究进展[J].现代肿瘤医学，2021，29（16）：2936-2939.
[13] 刘细帮，朱林芝，焦德敏，等.安罗替尼联合氯喹促进人非小细胞肺癌细胞系H1299凋亡[J].基础医学与临床，2021，41（7）：1018-1023.
[14] Han B，Li K，Zhao Y，et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer：a multicentre，randomised phase Ⅱ trial （ALTER0302） [J]. Br J Cancer，2018，118（5）：654-661.
[15] Liang H，Wang M. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer [J]. Cancer Manag Res，2019， 11：7707-7719.
[16] Lu J，Zhong H，Chu T，et al. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy [J]. Eur Respir J，2019，53（3）：1801562.
[17] 吕艺华，赵子龙，黄革红，等.安罗替尼联合伊立替康二线治疗小细胞肺癌的临床疗效及安全性[J].天津医药，2021，49（4）：436-440.
[18] 卢美君，康马飞，李碧慧，等.安罗替尼三线以上治疗非小细胞肺癌疗效观察[J].现代肿瘤医学，2021，29（8）：1332-1335.
[19] 宁瑞玲，何剑波，钟东美，等.盐酸安罗替尼治疗晚期非小细胞肺癌的疗效及安全性[J].现代肿瘤医学，2021， 29（14）：2442-2446.
[20] 李言冰，石鑫，蔡玲玉，等.卡瑞利珠单抗联合安罗替尼治疗小细胞肺癌的效果及安全性[J].中国当代医药，2022， 29（2）：82-84，88.
[21] 闻艺璇，梁利军，陈婷，等.安罗替尼临床应用研究进展[J].中华肿瘤防治杂志，2019，26（14）：979-985.
[22] Saito H，Fukuhara T，Furuya N，et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer （NEJ026）：interim analysis of an open-label，randomised，multicentre，phase 3 trial [J]. Lancet Oncol，2019，20（5）：625-635.
[23] 高恒兴，钟晓飞，张莉，等.DCE-MRI预测晚期非小细胞肺癌患者对安罗替尼的治疗反应[J].中国老年学杂志，2021，41（8）：1621-1624.
[24] 夏波，程志祥.盐酸安罗替尼治疗晚期非小细胞肺癌的研究进展[J].中国医药导报，2020，17（30）：53-55，63.
[25] Wang HY，Chu JF，Zhao Y，et al. A trial of the safety and efficacy of chemotherapy plus Anlotinib vs chemotherapy alone as second- or third-line salvage treatment for advanced non-small cell lung cancer [J]. Cancer Manag Res，2020，12：3827-3834.
[26] 张明，周木子，冀召帅，等.盐酸安罗替尼不良反应文献分析[J].中国医院药学杂志，2021，41（9）：940-943，958.
[27] 储节胜，徐冠军，时毓，等.安罗替尼对非小细胞肺癌患者肺功能的影响及安全性分析[J].中国当代医药，2021， 28（17）：100-102.
[28] 王亚梦，孟宇，师霄楠，等.盐酸安罗替尼治疗晚期原发性肝癌的临床疗效、安全性及预后分析[J].中华肝脏病杂志，2020，28（7）：619-624.
京公网安备 11010502046598号